Ascentage Pharma Group International (NASDAQ:AAPG) Upgraded at BTIG Research

BTIG Research upgraded shares of Ascentage Pharma Group International (NASDAQ:AAPG) to a strong-buy rating in a research note issued to investors on Wednesday,Zacks.com reports.

Several other analysts have also recently issued reports on the company. Lucid Cap Mkts upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. Truist Financial set a $51.00 price target on Ascentage Pharma Group International in a report on Monday, November 24th. Rodman & Renshaw started coverage on shares of Ascentage Pharma Group International in a report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price objective for the company. Finally, Oppenheimer began coverage on shares of Ascentage Pharma Group International in a research report on Thursday, December 4th. They set an “outperform” rating and a $45.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating and five have issued a Buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $48.00.

Ascentage Pharma Group International Stock Up 1.8%

NASDAQ:AAPG opened at $24.43 on Wednesday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53. The business’s 50-day simple moving average is $25.05 and its two-hundred day simple moving average is $31.18. Ascentage Pharma Group International has a 52 week low of $17.56 and a 52 week high of $48.45.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of hedge funds have recently made changes to their positions in AAPG. Tema Etfs LLC purchased a new position in shares of Ascentage Pharma Group International in the 2nd quarter worth approximately $610,000. UBS Group AG raised its holdings in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares during the period. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International during the 2nd quarter valued at $391,000. Citadel Advisors LLC bought a new stake in Ascentage Pharma Group International in the third quarter worth $383,000. Finally, XY Capital Ltd boosted its stake in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after buying an additional 12,530 shares during the period.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.